Patients
Deciphera Pharmaceuticals is committed to advancing improved treatments for patients with cancer. Our pipeline of tumor-targeted therapies and immuno-targeted therapies are being evaluated for the treatment of multiple cancer indications including:
GIST:
Gastrointestinal stromal tumors (GIST) are tumors of the gastrointestinal tract, most commonly found in the stomach or small intestine. According to the American Cancer Society, in 2015 approximately 5,000 patients were newly diagnosed with GIST in the United States (1.5 per 100,000 population) and a similar incidence rate may apply in European and other countries.[1]
Systemic Mastocytosis:
Mastocytosis is a disease characterized by an abnormal accumulation of mast cells, a type of white blood cell, located in peripheral tissues and organs. Mast cells store components that mediate inflammatory and allergic responses. There are several subtypes of the disease, and outcomes can vary significantly by subtype. While the exact number of patients suffering from all forms of mastocytosis, including urticaria pigmentosa, is not known, it is estimated that about 3,000 patients are newly diagnosed each year in the United States and about 30,000 patients live with the disease in the United States.[2]
Deciphera’s Systemic Mastocytosis Clinical Trial fact sheet
- [1] Zhao et al. J Gastrointest Oncol 2012;3(3):189-208. Estimates based on incidence rate extrapolated to population of selected major markets.
- [2] Cohen et al. British Journal of Haematology, 2014, 166, 521–528. Estimates based on incidence rate extrapolated to population of selected major markets.
